We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Getein Biotech, Inc.

Getein Biotech, Inc. is a fully integrated in vitro diagnostic company that develops, manufactures and distributes an... read more Featured Products: More products

Download Mobile App





Getein Introduces New MAGICL 6000 Chemiluminescence Immunoassay Analyzer at MEDICA 2022

By LabMedica International staff writers
Posted on 13 Nov 2022
Print article
Image: The new MAGICL 6000 chemiluminescence immunoassay analyzer introduced at MEDICA 2022 (Photo courtesy of Getein)
Image: The new MAGICL 6000 chemiluminescence immunoassay analyzer introduced at MEDICA 2022 (Photo courtesy of Getein)

Getein Biotech, Inc. (Nanjing, China) is introducing new POC solutions, including analyzers and rapid tests, at the 2022 edition of MEDICA, the world's largest trade fair for medical technology, being held from 14 to 17 November in Düsseldorf, Germany.

At MEDICA 2022, Getein is introducing MAGICL 6000, a compact and innovative chemiluminescence immunoassay analyzer, with optimal choice for mid to high-workflow laboratories that require a one-step chemiluminescence solution. Highly productive and compact, the instrument enables fully automated operation and provides the fastest testing speed of any device of its size. Getein is also showcasing Metis 600, a bench-top two in one immuno-hemanalysis and hematology modular system.

Among its range of POC platforms being highlighted at the event is the Getein 1600 fully-automated immunofluorescence quantitative analyzer which combined with bar-coded, ready-to-use strip cassettes, delivers accurate testing results in minutes. In conjunction with dedicated immunofluorescence test kits, the Getein 1600 automates the detection and quantification of markers for cardiovascular disease, renal diseases, inflammation, fertility, diabetes mellitus, bone metabolism, tumor and thyroid in a biological sample. Visitors to the company’s booth at MEDICA 2022 can also experience the Getein 1180 immunofluorescence quantitative analyzer that is used to measure the concentration of biomarkers in human whole blood, serum, plasma, urine, nasal swab, or saliva samples. The results can be used as an aid in clinical diagnosis of laboratory and POC testing and is applicable in emergency departments, clinical labs, outpatient departments, ICU, CCU, cardiology, ambulance, inpatient wards, etc.

Also on display at MEDICA 2022 are the Getein 1160 multi-channel POCT analyzer which has four incubation channels and one emergency test channel, along with a constant test environment with 32℃ to ensure more accurate test results. The Getein 1160 is applicable in emergency departments, clinical labs, outpatient departments, ICU, CCU, cardiology, ambulance, inpatient wards, etc. Alongside the Getein 1160, the company is demonstrating the Getein 208 hand-held integrated system that works with dedicated test kits made by Getein. Getein 208 is intended to detect and quantify specific chemical components in human blood serum, plasma, whole blood, capillary blood and urine samples through dry chemistry and fluorescence immunoassay. Getein is also showcasing rapid tests at MEDICA 2022, including its Monkeypox Virus Real-time PCR Kit which is used for the qualitative detection of MPV in serum or lesion exudate samples.

Related Links:
Getein Biotech, Inc. 

New
Gold Member
ZIKA Virus Test
ZIKA ELISA IgG
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
New
RNA/DNA Extraction Instrument
QIAcube Connect Instrument
New
Borrelia Burgdorferi Test
AESKULISA Borrelia-M

Print article

Channels

Microbiology

view channel
Image: Genetic testing can determine which drugs will work for patients with C. auris (Photo courtesy of Shutterstock)

Genetic Testing Could Improve Treatment for Virulent Multidrug-Resistant Fungus Candida Auris

Candida auris (C. auris), a multidrug-resistant yeast responsible for severe, life-threatening infections, was first identified in 2009. Since its discovery, it has spread globally, causing significant... Read more

Pathology

view channel
Image: The unique AI tool predicts cancer prognoses and responses to treatment (Photo courtesy of Shutterstock)

AI Tool Combines Data from Medical Images with Text to Predict Cancer Prognoses

The integration of visual data (such as microscopic and X-ray images, CT and MRI scans) with textual information (like exam notes and communications between doctors of different specialties) is a crucial... Read more

Technology

view channel
Image: Human tear film protein sampling methods (Photo courtesy of Clinical Proteomics. 2024 Mar 13;21:23. doi: 10.1186/s12014-024-09475-8)

New Lens Method Analyzes Tears for Early Disease Detection

Bodily fluids, including tears and saliva, carry proteins that are released from different parts of the body. The presence of specific proteins in these biofluids can be a sign of health issues.... Read more

Industry

view channel
Image: The investment is in line with Danaher’s aim to accelerate the transition to precision medicine with AI-enabled diagnostics

Danaher Partners with Healthcare AI Company Innovaccer on Novel Digital and Diagnostic Solutions

Danaher Diagnostics LLC and Danaher Ventures LLC, two subsidiaries of Danaher Corporation (Washington, DC, USA), has formed an investment partnership with healthcare artificial intelligence (AI) company... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.